Abstract
Using paired serum samples obtained from patients with illness associated with increases in anti-human coronavirus OC43 (HCoV-OC43) or anti-HCoV-229E antibodies, we examined the possibility of false-positive results detected in a recombinant severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein immunoglobulin G enzyme-linked immunosorbent assay (ELISA). Three of the 21 and 1 of the 7 convalescent-phase serum samples from persons with increases in antibodies against HCoV-OC43 and HCoV-229E, respectively, tested positive by the recombinant SARS-CoV nucleocapsid protein-based ELISA. None of these samples were found to contain a specific antibody in the recombinant SARS-CoV spike polypeptide-based Western blot assay.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
-
Retracted Publication
MeSH terms
-
Antibodies, Viral / blood
-
Blotting, Western
-
Coronavirus Nucleocapsid Proteins
-
Cross Reactions
-
Enzyme-Linked Immunosorbent Assay
-
False Positive Reactions
-
Humans
-
Membrane Glycoproteins / genetics
-
Membrane Glycoproteins / immunology*
-
Nucleocapsid Proteins / genetics
-
Nucleocapsid Proteins / immunology*
-
Peptides / genetics
-
Peptides / immunology
-
Recombinant Proteins / immunology*
-
Severe Acute Respiratory Syndrome / diagnosis*
-
Severe Acute Respiratory Syndrome / virology
-
Severe acute respiratory syndrome-related coronavirus / immunology*
-
Spike Glycoprotein, Coronavirus
-
Viral Envelope Proteins / genetics
-
Viral Envelope Proteins / immunology*
Substances
-
Antibodies, Viral
-
Coronavirus Nucleocapsid Proteins
-
Membrane Glycoproteins
-
Nucleocapsid Proteins
-
Peptides
-
Recombinant Proteins
-
Spike Glycoprotein, Coronavirus
-
Viral Envelope Proteins